Skip to main content
Journal of Hematology & Oncology logoLink to Journal of Hematology & Oncology
. 2022 Oct 31;15:159. doi: 10.1186/s13045-022-01369-2

Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial

Qian Jiang 1, Zongru Li 1, Yazhen Qin 1, Weiming Li 2, Na Xu 3, Bingcheng Liu 4, Yanli Zhang 5, Li Meng 6, Huanling Zhu 7, Xin Du 8, Suning Chen 9, Yang Liang 10, Yu Hu 2, Xiaoli Liu 3, Yongping Song 5, Lichuang Men 11, Zi Chen 11, Qian Niu 11, Hengbang Wang 11, Ming Lu 12, Dajun Yang 13,14, Yifan Zhai 11,12, Xiaojun Huang 1,15,16,17,
PMCID: PMC9623999  PMID: 36316695

Correction to: Journal of Hematology & Oncology (2022) 15:113 10.1186/s13045-022-01334-z

The original article [1] contained three erroneous citations and other minor typesetting errors in the text which have since been amended.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reference

  • 1.Jiang, et al. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2022;15:113. doi: 10.1186/s13045-022-01334-z. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Hematology & Oncology are provided here courtesy of BMC

RESOURCES